AG
MRTX

Advisor Group’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Advisor Group’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$887K Buy
6,881
+6,877
+171,925% +$663K 0.01% 1280
2019
Q3 		$0 Hold
4
– – ﹤0.01% 5473
2019
Q2 		$0 Hold
4
– – ﹤0.01% 5403
2019
Q1 		$0 Buy
+4
New +$272 ﹤0.01% 5366
2016
Q4 		– Sell
-1,000
Closed -$7K – 4654
2016
Q3 		$7K Hold
1,000
– – ﹤0.01% 3769
2016
Q2 		$5K Buy
+1,000
New +$15.9K ﹤0.01% 3807

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Advisor Group's MRTX Position: Q4 2019 in Review

Advisor Group increased its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 171,925% in Q4 2019, buying an estimated $663K and bringing the position to 6,881 shares worth $887K. The position accounts for 0.01% of the portfolio, ranked #1280.

Advisor Group first reported a position in MRTX in Q2 2016 and has held it in 6 quarters since. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

  • Advisor Group held 6,881 shares of Mirati Therapeutics, Inc. Common Stock worth $887K as of Q4 2019.
  • Advisor Group bought 6,877 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $663K.
  • Mirati Therapeutics, Inc. Common Stock made up 0.01% of Advisor Group's portfolio in Q4 2019, its #1280 holding.
  • Advisor Group first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2016 and has held it in 6 quarters since.
  • 190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.